GP: Envelope glycoprotein
Protein in Zaire ebolavirus (strain Mayinga-76) (ZEBOV) (Zaire Ebola virus) that 10 drugs act on.
- Drugs that act on it: 10
- Approved: 7
- In phases 1 to 3: 3
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on GP, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 7
- Other 3
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
| Atoltivimab | Approved | — | Antibody | Inhibitor | 2 |
| Maftivimab | Approved | — | Antibody | Inhibitor | 2 |
| Odesivimab | Approved | — | Antibody | Inhibitor | 2 |
| Adenovirus type 26 encoding ebola virus glycoprotein | Approved | — | Vaccine component | Vaccine antigenEnvelope glycoprotein vaccine antigen | 0 |
| Ansuvimab | Approved | Ridgeback Biotherapeutics | Antibody | Binding agentEnvelope glycoprotein binding agent | 0 |
| Vaccinia virus, modified encoding ebola virus glycoprotein and nucleoprotein | Approved | — | Vaccine component | Vaccine antigenEnvelope glycoprotein vaccine antigen | 0 |
| Vesicular stomatitis virus encoding ebola virus glycoprotein | Approved | — | Vaccine component | Vaccine antigenEnvelope glycoprotein vaccine antigen | 0 |
| Cosfroviximab | Phase 2 | — | Antibody | Inhibitor | 0 |
| Larcaviximab | Phase 2 | — | Antibody | Inhibitor | 0 |
| Porgaviximab | Phase 2 | — | Antibody | Inhibitor | 0 |
| EBOla Post-Exposure Prophylaxis | Atoltivimab, Maftivimab, Odesivimab | Phase 3 | Not yet recruiting | ANRS, Emerging Infectious Diseases | Feb 24, 2025 |
| Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers | Atoltivimab, Maftivimab, Odesivimab | Phase 2 | Not yet recruiting | ANRS, Emerging Infectious Diseases | Jan 21, 2022 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4105829, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets